{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:20:02Z","timestamp":1780676402196,"version":"3.54.1"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40265-021-01469-2","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T01:50:35Z","timestamp":1613699435000},"page":"555-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-0026","authenticated-orcid":false,"given":"Christo","family":"Cimino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikunj","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"3","key":"1469_CR1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871526511313030008","volume":"13","author":"V Gupta","year":"2013","unstructured":"Gupta V, Yassin MH. Infection and hemodialysis access: an updated review. Infect Disord Drug Targets. 2013;13(3):196\u2013205.","journal-title":"Infect Disord Drug Targets."},{"issue":"2","key":"1469_CR2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00007691-198706000-00004","volume":"9","author":"F Keller","year":"1987","unstructured":"Keller F, Borner K, Schwarz A, Offermann G, Lode H. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit. 1987;9(2):148\u201353.","journal-title":"Ther Drug Monit."},{"issue":"5","key":"1469_CR3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526\u201333.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"1469_CR4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.2013091028","volume":"25","author":"IM Zacharioudakis","year":"2014","unstructured":"Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Meta-analysis of methicillin-resistant Staphylococcus aureus colonization and risk of infection in dialysis patients. J Am Soc Nephrol. 2014;25(9):2131\u201341.","journal-title":"J Am Soc Nephrol."},{"issue":"Suppl 1","key":"1469_CR5","first-page":"S1","volume":"48","author":"National Kidney Foundation","year":"2006","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S1\u2013322.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"1469_CR6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000489923","volume":"8","author":"WS El Nekidy","year":"2018","unstructured":"El Nekidy WS, Soong D, Kadri A, Tabbara O, Ibrahim A, Ghazi IM. Salvage of hemodialysis catheter in Staphylococcal bacteremia: case series, revisiting the literature, and the role of the pharmacist. Case Rep Nephrol Dial. 2018;8(2):121\u20139.","journal-title":"Case Rep Nephrol Dial."},{"issue":"2","key":"1469_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2015.993381","volume":"16","author":"AK Thabit","year":"2015","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159\u201377.","journal-title":"Expert Opin Pharmacother."},{"key":"1469_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00270-002-2628-z","volume":"26","author":"CF Gonsalves","year":"2003","unstructured":"Gonsalves CF, Eschelman DJ, Sullivan KL, DuBois N, Bonn J. Incidence of central vein stenosis and occlusion following upper extremity PICC and port placement. Cardiovasc Intervent Radiol. 2003;26:123\u20137.","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"5","key":"1469_CR9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","volume":"29","author":"BH Heintz","year":"2009","unstructured":"Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562\u201377.","journal-title":"Pharmacotherapy."},{"key":"1469_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/cc1516","volume":"6","author":"V Launay-Vacher","year":"2002","unstructured":"Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care. 2002;6:313\u20136.","journal-title":"Crit Care."},{"key":"1469_CR11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ajhp\/61.17.1812","volume":"61","author":"AB Pai","year":"2004","unstructured":"Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm. 2004;61:1812\u20136.","journal-title":"Am J Health Syst Pharm."},{"issue":"S2","key":"1469_CR12","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/hdi.12702","volume":"22","author":"S Haroon","year":"2018","unstructured":"Haroon S, Davenport A. Choosing a dialyzer: what clinicians need to know. Hemodial Int. 2018;22(S2):S65\u201374.","journal-title":"Hemodial Int."},{"issue":"11","key":"1469_CR13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm."},{"key":"1469_CR14","first-page":"986","volume":"89","author":"N Klansuwan","year":"2006","unstructured":"Klansuwan N, Ratanajamit C, Kasiwong S, Wangsiripaisan A. Clearance of vancomycin during high-efficiency hemodialysis. J Med Assoc Thai. 2006;89:986\u201391.","journal-title":"J Med Assoc Thai."},{"key":"1469_CR15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.ajkd.2005.07.018","volume":"46","author":"RE Ariano","year":"2005","unstructured":"Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis. 2005;46:681\u20137.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"1469_CR16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/cir322","volume":"53","author":"M Brown","year":"2011","unstructured":"Brown M, Polisetty R, Gracely EJ, Cuhaci B, Schlecht HP. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis. 2011;53(2):164\u20136.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"1469_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000453005","volume":"135","author":"L Ghouti-Terki","year":"2017","unstructured":"Ghouti-Terki L, Chasseuil E, Rabot N, et al. Vancomycin during the last hour of the hemodialysis session: a pharmacokinetic analysis. Nephron. 2017;135(4):261\u20137.","journal-title":"Nephron."},{"issue":"3","key":"1469_CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hdi.12637","volume":"22","author":"HA Nyman","year":"2018","unstructured":"Nyman HA, Agarwal A, Senekjian HO, Leypoldt JK, Cheung AK. Removal of vancomycin administered during dialysis by a high-flux dialyzer. Hemodial Int. 2018;22(3):383\u20137.","journal-title":"Hemodial Int."},{"issue":"21","key":"1469_CR19","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2146\/ajhp150051","volume":"72","author":"P Crew","year":"2015","unstructured":"Crew P, Heintz SJ, Heintz BH. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis. Am J Health Syst Pharm. 2015;72(21):1856\u201364.","journal-title":"Am J Health Syst Pharm."},{"key":"1469_CR20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/cis458","volume":"55","author":"SA Zelenitsky","year":"2012","unstructured":"Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis. Clin Infect Dis. 2012;55:527\u201333.","journal-title":"Clin Infect Dis."},{"key":"1469_CR21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijantimicag.2017.12.017","volume":"51","author":"K Hui","year":"2018","unstructured":"Hui K, Upjohn L, Nalder M, et al. Vancomycin dosing in chronic high-flux haemodialysis: a systematic review. Int J Antimicrob Agents. 2018;51:678\u201386.","journal-title":"Int J Antimicrob Agents."},{"issue":"5","key":"1469_CR22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciu971","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015;60(5):787\u201396.","journal-title":"Clin Infect Dis."},{"key":"1469_CR23","unstructured":"Vibativ (telavancin) [package insert]. San Francisco: Theravance Inc; 2009."},{"issue":"7","key":"1469_CR24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40262-017-0623-4","volume":"57","author":"V Al Jalali","year":"2018","unstructured":"Al Jalali V, Zeitlinger M. Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet. 2018;57(7):797\u2013816.","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"1469_CR25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.diagmicrobio.2014.09.002","volume":"80","author":"SL Barriere","year":"2014","unstructured":"Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014;80(4):327\u20139.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"1469_CR26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00228-015-1847-6","volume":"71","author":"PD Worboys","year":"2015","unstructured":"Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015;71:707\u201314.","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"1469_CR27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jac\/dkx437","volume":"73","author":"NS Britt","year":"2018","unstructured":"Britt NS, Tirmizi S, Ritchie DJ, et al. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. J Antimicrob Chemother. 2018;73(3):764\u20137.","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"1469_CR28","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/AAC.02330-13","volume":"58","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014;58(4):2030\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR29","unstructured":"Cubicin (daptomycin for injection) package insert. Whitehouse Station: Merck & Co., Inc.; 2018."},{"issue":"4","key":"1469_CR30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","volume":"19","author":"M Falcone","year":"2013","unstructured":"Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19(4):732\u20139.","journal-title":"J Infect Chemother."},{"key":"1469_CR31","unstructured":"Bhavnani SM, Ambrose PG, Rubino CM, et al. Toxicodynamics of daptomycin in patients with bacteremia and\/or endocarditis. In: Poster presented at the 46th international conference on antimicrobial agents and chemotherapy; 27\u201330 Sep 2006: San Francisco."},{"key":"1469_CR32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","volume":"25","author":"NN Salama","year":"2010","unstructured":"Salama NN, Segal JH, Churchwell MD, et al. Single-dose daptomycin pharmacokinetics in chronic hemodialysis patients. Nephrol Dial Transplant. 2010;25:1279\u201384.","journal-title":"Nephrol Dial Transplant."},{"key":"1469_CR33","first-page":"63","volume":"75","author":"DP Benziger","year":"2011","unstructured":"Benziger DP, Pertel PE, Donovan J, et al. Pharmacokinetics and safety of multiple doses of daptomycin 6mg\/kg in non-infected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol. 2011;75:63\u20139.","journal-title":"Clin Nephrol."},{"issue":"4","key":"1469_CR34","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/AAC.01224-10","volume":"55","author":"N Patel","year":"2011","unstructured":"Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2011;55(4):1677\u201383.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"1469_CR35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1177\/1060028013503110","volume":"47","author":"M Haselden","year":"2013","unstructured":"Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. Ann Pharmacother. 2013;47(10):1342\u20137.","journal-title":"Ann Pharmacother."},{"issue":"2","key":"1469_CR36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","volume":"57","author":"JM Butterfield","year":"2013","unstructured":"Butterfield JM, Mueller BA, Patel N, et al. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013;57(2):864\u201372.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"1469_CR37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028019865873","volume":"545","author":"BM Hoff","year":"2020","unstructured":"Hoff BM, Maker JH, Dager W, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy. Ann Pharmacother. 2020;545(1):43\u201355.","journal-title":"Ann Pharmacother."},{"key":"1469_CR38","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.01650309","volume":"4","author":"NN Salama","year":"2009","unstructured":"Salama NN, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol. 2009;4:1190\u20134.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"1469_CR39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1592\/phco.31.7.665","volume":"31","author":"BA Mueller","year":"2011","unstructured":"Mueller BA, Crompton JA, Donovan BJ, Yankalev S, Lamp KC. Safety of daptomycin in patients receiving hemodialysis. Pharmacotherapy. 2011;31(7):665\u201372.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"1469_CR40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1053\/j.ajkd.2017.05.011","volume":"70","author":"J Diolez","year":"2017","unstructured":"Diolez J, Venisse N, Belmouaz S, Bauwens MA, Bridoux F, Beraud G. Pilot pharmacokinetic study of high-dose daptomycin in hemodialysis patients with infected medical devices. Am J Kidney Dis. 2017;70(5):732\u20134.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"1469_CR41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40121-014-0049-3","volume":"3","author":"W So","year":"2014","unstructured":"So W, Kuti JL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI). Infect Dis Ther. 2014;3(2):269\u201379.","journal-title":"Infect Dis Ther."},{"issue":"7","key":"1469_CR42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/cid\/cir031","volume":"52","author":"JD Turnidge","year":"2011","unstructured":"Turnidge JD. Cefazolin and Enterobacteriaceae: rationale for revised susceptibility testing breakpoints. Clin Infect Dis. 2011;52(7):917\u201324.","journal-title":"Clin Infect Dis."},{"key":"1469_CR43","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/jps.2600641202","volume":"64","author":"CH Nightingale","year":"1975","unstructured":"Nightingale CH, Greene DS, Quintiliani R. Pharmacokinetics and clinical uses of cephalosporin antibiotics. J Pharm Sci. 1975;64:1899\u2013926.","journal-title":"J Pharm Sci."},{"key":"1469_CR44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/AAC.19.4.613","volume":"19","author":"WM Scheld","year":"1981","unstructured":"Scheld WM, Spyker DA, Donowitz GR, Bolton WK, Sande MA. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981;19:613\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"1469_CR45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano GL. Antimicrobial pharmacodynamics: critical interactions of \u201cbug and drug.\u201d Nat Rev Microbiol. 2004;2(4):289\u2013300.","journal-title":"Nat Rev Microbiol."},{"issue":"6","key":"1469_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","volume":"39","author":"MG Sinnollareddy","year":"2012","unstructured":"Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. \u03b2-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol. 2012;39(6):489\u201396.","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"4","key":"1469_CR47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","volume":"31","author":"PS McKinnon","year":"2008","unstructured":"McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31(4):345\u201351.","journal-title":"Int J Antimicrob Agents."},{"issue":"5","key":"1469_CR48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","volume":"45","author":"SL Aitken","year":"2015","unstructured":"Aitken SL, Altshuler J, Guervil DJ, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015;45(5):541\u20134.","journal-title":"Int J Antimicrob Agents."},{"issue":"3","key":"1469_CR49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","volume":"50","author":"VH Tam","year":"2002","unstructured":"Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002;50(3):425\u20138.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"1469_CR50","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","volume":"51","author":"C Li","year":"2007","unstructured":"Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51(5):1725\u201330.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"1469_CR51","first-page":"429","volume":"75","author":"G Wong","year":"2020","unstructured":"Wong G, Taccone F, Villois P, et al. \u03b2-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. J Antimicrob Chemother. 2020;75(2):429\u201333.","journal-title":"J Antimicrob Chemother."},{"key":"1469_CR52","unstructured":"Ancef (cefazolin for injection) package insert. Research Triangle Park: GlaxoSmithKline; 2004."},{"key":"1469_CR53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190\u20136.","journal-title":"Clin Infect Dis."},{"key":"1469_CR54","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/ndt\/14.8.2050","volume":"14","author":"D Kuypers","year":"1999","unstructured":"Kuypers D, Vanwalleghem J, Maes B, Messiaen T, Vanrenterghem Y, Peetermans WE. Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. Nephrol Dial Transplant. 1999;14:2050\u20131.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1469_CR55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/ajhp\/60.2.178","volume":"60","author":"JW Ahern","year":"2003","unstructured":"Ahern JW, Possidente CJ, Hood V, Alston WK. Cefazolin dosing protocol for patients receiving long-term hemodialysis. Am J Health Syst Pharm. 2003;60(2):178\u201381.","journal-title":"Am J Health Syst Pharm."},{"issue":"1","key":"1469_CR56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1542-4758.2010.00507.x","volume":"15","author":"CJ Renaud","year":"2011","unstructured":"Renaud CJ, Lin X, Subramanian S, Fisher DA. High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia. Hemodial Int. 2011;15(1):63\u20138.","journal-title":"Hemodial Int."},{"key":"1469_CR57","unstructured":"Lexi-Drugs. Hudson: Lexicomp; 2020. http:\/\/online.lexi.com\/. Accessed 28 July 2020."},{"key":"1469_CR58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/ajkd.1998.v32.pm9740155","volume":"32","author":"MA Fogel","year":"1998","unstructured":"Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis. 1998;32:401\u20139.","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"1469_CR59","first-page":"417","volume":"43","author":"RL Yost","year":"1977","unstructured":"Yost RL, Lee JD, O\u2019Leary JP. Convulsions associated with sodium cefazolin: a case report. Am Surg. 1977;43(6):417\u201320.","journal-title":"Am Surg."},{"key":"1469_CR60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/ajkd.1998.v32.pm9740156","volume":"32","author":"MA Marx","year":"1998","unstructured":"Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis. 1998;32:410\u20134.","journal-title":"Am J Kidney Dis."},{"key":"1469_CR61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0272-6386(01)80126-8","volume":"37","author":"KM Sowinski","year":"2001","unstructured":"Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis. 2001;37:766\u201376.","journal-title":"Am J Kidney Dis."},{"key":"1469_CR62","unstructured":"Fortaz (ceftazidime for injection) package insert. Buena: Teligent Pharma, Inc.; 2017."},{"key":"1469_CR63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/AAC.25.2.201","volume":"25","author":"LS Welage","year":"1984","unstructured":"Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984;25:201\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR64","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/AAC.25.5.638","volume":"25","author":"A Leroy","year":"1984","unstructured":"Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humbert G. Pharmacokinetics of ceftazidime in normal and uraemic subjects. Antimicrob Agents Chemother. 1984;25:638\u201342.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR65","first-page":"142","volume":"24","author":"P Nikolaidis","year":"1985","unstructured":"Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol. 1985;24:142\u20136.","journal-title":"Clin Nephrol."},{"key":"1469_CR66","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","volume":"68","author":"AE Muller","year":"2013","unstructured":"Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68:900\u20136.","journal-title":"J Antimicrob Chemother."},{"key":"1469_CR67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","volume":"22","author":"WA Craig","year":"1995","unstructured":"Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89\u201396.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"1469_CR68","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.39.8.1797","volume":"33","author":"DM Cappelletty","year":"1995","unstructured":"Cappelletty DM, Kang L, Palmer S, et al. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;33:1797\u2013801.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.38.5.931","volume":"38","author":"JW Mouton","year":"1994","unstructured":"Mouton JW, Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jac\/12.suppl_A.241","volume":"12","author":"D Hoffler","year":"1983","unstructured":"Hoffler D, Koeppe P, Williams K. Pharmacokinetics of ceftazidime in normal and impaired renal function. J Antimicrob Chemother. 1983;12:241\u20135.","journal-title":"J Antimicrob Chemother."},{"key":"1469_CR71","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1128\/AAC.00474-13","volume":"57","author":"AS Loo","year":"2013","unstructured":"Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux haemodialysis. Antimicrob Agents Chemother. 2013;57:5854\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"1469_CR72","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/jac\/dkz096","volume":"74","author":"H Maxwell-Scott","year":"2019","unstructured":"Maxwell-Scott H, Thangarajah R, Arnold A, Wade P, Klein JL. Successful treatment of Pseudomonas aeruginosa infective endocarditis via haemodialysis outpatient parenteral antimicrobial therapy: case report. J Antimicrob Chemother. 2019;74(6):1757\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"1469_CR73","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/AAC.37.8.1696","volume":"37","author":"JA Washington","year":"1993","unstructured":"Washington JA, Jones RN, Gerlach EH. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother. 1993;37:1696\u2013700.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/sdi.12094","volume":"26","author":"DP Calfee","year":"2013","unstructured":"Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial. 2013;26:447\u201356.","journal-title":"Semin Dial."},{"issue":"5","key":"1469_CR75","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","volume":"58","author":"JF Roos","year":"2006","unstructured":"Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother. 2006;58(5):987\u201393.","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"1469_CR76","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1128\/AAC.36.12.2676","volume":"36","author":"J Cronqvist","year":"1992","unstructured":"Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother. 1992;36(12):2676\u201380.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"1469_CR77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1592\/phco.28.8.977","volume":"28","author":"LM Maynor","year":"2008","unstructured":"Maynor LM, Carl DE, Matzke GR, et al. An in-vivo-in-vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis. Pharmacotherapy. 2008;28(8):977\u201383.","journal-title":"Pharmacotherapy."},{"key":"1469_CR78","unstructured":"Maxipime (cefepime for injection) package insert. Lake Forest: Hospira, Inc.; 2012."},{"key":"1469_CR79","volume-title":"Drug prescribing in renal failure: dosing guidelines for adults and children","author":"GA Aronoff","year":"2007","unstructured":"Aronoff GA, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.","edition":"5"},{"key":"1469_CR80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002280050721","volume":"56","author":"S Schmaldienst","year":"2000","unstructured":"Schmaldienst S, Traunmuller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol. 2000;56:61\u20134.","journal-title":"Eur J Clin Pharmacol."},{"key":"1469_CR81","first-page":"140","volume":"10","author":"B Meyer","year":"2005","unstructured":"Meyer B, Guttmann C, Dittrich E. Intermittent administration of beta-lactam antibiotics for treatment of severe infection in hemodialysis patients. Eur J Med Res. 2005;10:140\u20134.","journal-title":"Eur J Med Res."},{"key":"1469_CR82","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/ndt\/14.9.2265","volume":"14","author":"KM Wong","year":"1999","unstructured":"Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant. 1999;14:2265.","journal-title":"Nephrol Dial Transplant."},{"key":"1469_CR83","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","volume":"54","author":"F Lamoth","year":"2010","unstructured":"Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54:4360\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"1469_CR84","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.ajkd.2012.01.012","volume":"59","author":"KK Perez","year":"2012","unstructured":"Perez KK, Hughes DW, Maxwell PR, Green K, Lewis JS 2nd. Cefepime for Gram-negative bacteremia in long-term hemodialysis: a single-center experience. Am J Kidney Dis. 2012;59(5):740\u20132.","journal-title":"Am J Kidney Dis."},{"key":"1469_CR85","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-016-0048-y","volume":"17","author":"E Descombes","year":"2016","unstructured":"Descombes E, Martins F, Hemett OM, Erard V, Chuard C. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. BMC Pharmacol Toxicol. 2016;17:4.","journal-title":"BMC Pharmacol Toxicol."},{"key":"1469_CR86","unstructured":"Invanz (ertapenem for injection) [package insert]. Whitehouse Station: Merck & Co, Inc; 2012."},{"key":"1469_CR87","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/0091270006291839","volume":"46","author":"GC Mistry","year":"2006","unstructured":"Mistry GC, Majumdar AK, Swan S, et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients with hemodialysis. J Clin Pharmacol. 2006;46:1128\u201338.","journal-title":"J Clin Pharmacol."},{"key":"1469_CR88","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","volume":"46","author":"AK Majumdar","year":"2002","unstructured":"Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002;46:3506\u201311.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 2","key":"1469_CR89","first-page":"ii23","volume":"53","author":"DE Nix","year":"2004","unstructured":"Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(Suppl 2):ii23\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"1469_CR90","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/590064","volume":"47","author":"DP Nicolau","year":"2008","unstructured":"Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47:S32\u201340.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"1469_CR91","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of carbapenems. Drugs. 2007;67(7):1027\u201352.","journal-title":"Drugs."},{"key":"1469_CR92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.diagmicrobio.2006.06.014","volume":"57","author":"CR Ong","year":"2007","unstructured":"Ong CR, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Mirobiol Infec Dis. 2007;57:153\u201361.","journal-title":"Diagn Mirobiol Infec Dis."},{"key":"1469_CR93","first-page":"63","volume":"74","author":"WA Craig","year":"1990","unstructured":"Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63\u201370.","journal-title":"Scand J Infect Dis Suppl."},{"issue":"9","key":"1469_CR94","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1128\/AAC.41.9.2053","volume":"41","author":"M Manduru","year":"1997","unstructured":"Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997;41(9):2053\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR95","unstructured":"Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne: Clinical Laboratory Standards Institute; 2020."},{"key":"1469_CR96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/jcpt.12239","volume":"40","author":"KH Lee","year":"2015","unstructured":"Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential risk for systemic toxicity in haemodialysis patients\u2014case reports and literature reviews. J Clin Pharm Ther. 2015;40:240\u20134.","journal-title":"J Clin Pharm Ther."},{"key":"1469_CR97","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5414\/CN107247","volume":"80","author":"W Min-Jie","year":"2013","unstructured":"Min-Jie W, Chih-Chen S, Tom C, et al. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in two patients with advanced renal failure. Clin Nephrol. 2013;80:474\u20138.","journal-title":"Clin Nephrol."},{"issue":"1","key":"1469_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1060028020938059","volume":"55","author":"WS El Nekidy","year":"2021","unstructured":"El Nekidy WS, Elrafaei H, Lee St. John TJ, et al. Ertapenem neurotoxicity in hemodialysis patients\u2014safe and effective dosing is still needed: a retrospective study and literature review. Ann Pharmacother. 2021;55(1):52\u20138. https:\/\/doi.org\/10.1177\/1060028020938059.","journal-title":"Ann Pharmacother."},{"issue":"4","key":"1469_CR99","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5414\/CN108071","volume":"80","author":"CJ Geerlings","year":"2013","unstructured":"Geerlings CJ, de Man P, Rietveld AP, Touw DJ, Cohen Tervaert JW. A practical thrice weekly ertapenem dosage regimen for chronic hemodialysis patients? Clin Nephrol. 2013;80(4):312.","journal-title":"Clin Nephrol."},{"issue":"10","key":"1469_CR100","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/ndt\/gfy166","volume":"34","author":"LM Hsaiky","year":"2018","unstructured":"Hsaiky LM, Salinitri FD, Wong J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Nephrol Dial Transplant. 2018;34(10):1766\u201372.","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"1469_CR101","first-page":"e01427","volume":"63","author":"YF Ueng","year":"2019","unstructured":"Ueng YF, Wang HJ, Wu SC, Ng YY. A thrice-weekly ertapenem regimen is practical for hemodialysis patients. Antimicrob Agents Chemother. 2019;63(12):e01427-e1519.","journal-title":"Antimicrob Agents Chemother."},{"key":"1469_CR102","doi-asserted-by":"crossref","first-page":"e00748","DOI":"10.1016\/j.idcr.2020.e00748","volume":"20","author":"WS El Nekidy","year":"2020","unstructured":"El Nekidy WS, Soong D, Mooty M, Ghazi IM. Treatment of recurrent urinary tract infections in anuric hemodialysis patient, do we really need antimicrobial urinary concentrations? IDCases. 2020;20:e00748.","journal-title":"IDCases."},{"key":"1469_CR103","unstructured":"Gentamicin injection [package insert]. Lake Zurich: Fresenius Kabi USA, LLC; 2013."},{"key":"1469_CR104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1345\/aph.1G064","volume":"40","author":"WE Dager","year":"2006","unstructured":"Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother. 2006;40:9\u201314.","journal-title":"Ann Pharmacother."},{"key":"1469_CR105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.ki.5002295","volume":"72","author":"L Feldman","year":"2007","unstructured":"Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007;72:359\u201363.","journal-title":"Kidney Int."},{"issue":"2","key":"1469_CR106","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0272-6386(99)70347-1","volume":"34","author":"NB Amin","year":"1999","unstructured":"Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis. 1999;34(2):222\u20137.","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"1469_CR107","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0091270006292987","volume":"46","author":"MM Teigen","year":"2006","unstructured":"Teigen MM, Duffull S, Dang L, Johnson DW. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006;46(11):1259\u201367.","journal-title":"J Clin Pharmacol."},{"key":"1469_CR108","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.02920707","volume":"3","author":"KM Sowinski","year":"2008","unstructured":"Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3:355\u201361.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"1469_CR109","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2215\/CJN.01600407","volume":"2","author":"OH Kamel Mohamed","year":"2007","unstructured":"Kamel Mohamed OH, Wahba IM, Watnick S, et al. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Clin J Am Soc Nephrol. 2007;2(4):694\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"1469_CR110","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkv428","volume":"71","author":"L Zhuang","year":"2016","unstructured":"Zhuang L, He Y, Xia H, Liu Y, Sy SK, Derendorf H. Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother. 2016;71(4):1012\u201321.","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"1469_CR111","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","volume":"38","author":"CM Bland","year":"2018","unstructured":"Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38(12):1229\u201338.","journal-title":"Pharmacotherapy."},{"key":"1469_CR112","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ackd.2010.05.007","volume":"17","author":"RF Eyler","year":"2010","unstructured":"Eyler RF, Mueller BA. Antibiotic pharmacokinetic and pharmacodynamics considerations in patients with kidney disease. Adv Chronic Kidney Dis. 2010;17:392\u2013403.","journal-title":"Adv Chronic Kidney Dis."},{"issue":"3","key":"1469_CR113","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000237778","volume":"24","author":"RD Meyer","year":"1978","unstructured":"Meyer RD, Lewis RP, Finegold SM. Amikacin therapy of serious gram-negative bacillary infections in chronic hemodialysis patients. Chemotherapy. 1978;24(3):172\u20138.","journal-title":"Chemotherapy"},{"issue":"5","key":"1469_CR114","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00003246-198805000-00010","volume":"16","author":"DK Armstrong","year":"1988","unstructured":"Armstrong DK, Hodgman T, Visconti JA, Reilley TE, Garner WL, Dasta JF. Hemodialysis of amikacin in critically ill patients. Crit Care Med. 1988;16(5):517\u201320.","journal-title":"Crit Care Med."},{"issue":"11","key":"1469_CR115","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1345\/aph.1Q403","volume":"45","author":"BH Heintz","year":"2011","unstructured":"Heintz BH, Thompson GR 3rd, Dager WE. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices. Ann Pharmacother. 2011;45(11):1338\u201345.","journal-title":"Ann Pharmacother."},{"key":"1469_CR116","unstructured":"Diflucan (fluconazole) [package insert]. New York: Pfizer, Inc; 2020."},{"issue":"11","key":"1469_CR117","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/ndt\/gfg363","volume":"18","author":"L Cousin","year":"2003","unstructured":"Cousin L, Berre ML, Launay-Vacher V, Izzedine H, Deray G. Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant. 2003;18(11):2227\u201331.","journal-title":"Nephrol Dial Transplant."},{"key":"1469_CR118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/BF00265934","volume":"42","author":"S Oono","year":"1992","unstructured":"Oono S, Tabei K, Tetsuka T, Asano Y. The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol. 1992;42:667\u201370.","journal-title":"Eur J Clin Pharmacol."},{"key":"1469_CR119","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V62242","volume":"6","author":"T Berl","year":"1995","unstructured":"Berl T, Wilner KD, Gardner M, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol. 1995;6:242\u20137.","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"1469_CR120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5301\/jva.5000368","volume":"16","author":"M B\u00f6hlke","year":"2015","unstructured":"B\u00f6hlke M, Uliano G, Barcellos FC. Hemodialysis catheter-related infection: prophylaxis, diagnosis and treatment. J Vasc Access. 2015;16(5):347\u201355.","journal-title":"J Vasc Access."},{"issue":"2","key":"1469_CR121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1751143714564816","volume":"16","author":"S Shah","year":"2015","unstructured":"Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015;16(2):147\u201353.","journal-title":"J Intensive Care Soc."},{"key":"1469_CR122","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ki.1989.141","volume":"35","author":"DM Lanese","year":"1989","unstructured":"Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int. 1989;35:1409\u201312.","journal-title":"Kidney Int."},{"key":"1469_CR123","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp100410","volume":"68","author":"JV Leong","year":"2011","unstructured":"Leong JV, Boro MS, Winter M. Determining vancomycin clearance in overweight and obese population. Am J Health Syst Pharm. 2011;68:599\u2013603.","journal-title":"Am J Health Syst Pharm."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01469-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:08:36Z","timestamp":1744715316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01469-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01469-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christo Cimino, Yvonne Burnett, Nikunj Vyas, and Anne H. Norris have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors contributed to the literature review and preparation of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}